VOOPOO
2.12.2021 10:37:10 CET | Business Wire | Press release
In November, VOOPOO announced the overseas launch of the DRAG S/X PnP-X KIT. The product carries out comprehensive technical upgrading on the basis of DRAG S/X, endows the core concept of "Chivalry" in product design, and pays tribute to the glory and virtue of knights.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211202005381/en/
Originated from the spirit of martial arts of German in the Middle Ages, the spirit of chivalry was then embodied in soldiers of the European battlefield in the 11th century, and guards of emperors and warriors of Christ. Nowadays, chivalry is culturally continued and nobly expressed as gentleman demeanor. Despite passage of time, the only constant is the faith that knight loyally holds and eight virtues of knights flowing in their blood. After learning about this legendary medieval history and digging out the core of chivalry, VOOPOO design and R&D personnel were deeply touched. The four core propositions of " Honor", " Valor", "Justice" and "Spirituality" were included in DRAG S/X PnP-X KIT product for consumers to discover. Every vaping is a fusion of VOOPOO and the connotation of the knight, and every piece of cloud is a spiritual portrait of the knight who rushes to the battlefield heroically.
DRAG S/X PnP-X KIT selects five new knight colors, each of which implies a rich design language. Shield Gold--Knight Templar for Defending Justice. Knight Red--Masked Knight for Pursuit Fairness. Knight Chestnut--Dragon Knight for Defending Glory .Eagle Black--Black Knight for Brave and Fearless. Knight Gray--Paladin for Spirituality.
PnP-X Pod displays knight’s spirituality. The metal materials and knob-filling on the top are upgraded, and the 510 drip tip can be replaced at any time. It is anti-leakage, more convenient, and more flexible. Radiating knight spirituality, PnP-X Pod will give you an enjoyable experience in vaping.
The knight series products bring an "Infinite Airflow System" that supports the adjustment of any airway. More than that, knight symbolizes of bravery and heroism. DRAG S/X PnP-X KIT embodies the knight’s valor spirit. It is equipped with a powerful GENE.TT chip, and adjustable power ranging from 5-60/80w. The product can be started in 0.001 second. The hardware is powerful enough that every knight can charge into the battle, with no worries.
The mission of the knight is to guard the country and territory, glory, and faith, and the beloved princess in their hearts. DRAG S/X PnP-X KIT fitted with 2500 mAh built-in battery and 18650 external battery respectively. The Type-C 5V/2A fast charging interface gives every knight full blood for them to resurrect in an instant. To guard the DRAG S/X PnP-X KIT is to guard the spirit of the knight, the cultural connotation of which has been inherited and innovated for thousands of years.
DRAG S/X PnP-X KIT has been upgraded based on DARG S&DARG X. The biggest highlight is the comprehensive upgrade of the atomizer. For one thing, the PnP X Pod has upgraded the metal decorative ring with knight-style texture. For another, the knob-filling on the top, which is more convenient. Anti-leakage design is more compact, and the 510 drip tip can be replaced at any time. In short, the upgrade of DRAG S/X PnP-X KIT is comprehensive, and is worthy of buying. At the same time, a vaper who likes the appearance of knights can't miss this flagship product with "chivalry spirit." Let us pay tribute to the honor of knights together!
Positioning of DRAG S/X PnP-X KIT and DARG S/X PRO is different. DARG S/X PRO is a top-fitting product for professional vapers who want to experience higher power and bigger cloud.
Founded in 2017, VOOPOO has rapidly grown within a short period of time and is now selling worldwide. VOOPOO is a high-tech enterprise integrating R&D, design, production and brand operations. It has four flagship product series: DRAG, VINCI, ARGUS and V Series. VOOPOO has more than 3000 employees worldwide and its business covers more than 70 countries and regions in North America, Europe and Asia.
WARNING: This product may be used with e-liquid products containing nicotine. Nicotine is an addictive chemical.
For more information, please visit https://www.voopoo.com/ , and follow our IG , Facebook and TikTok pages.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211202005381/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN® APN6.8.2026 06:30:00 CEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom